Selected FDA-Approved Imaging Biomarkers
| Probe | Target | Process | Application | Biomarker type |
| 18F-FDG | Hexokinase 2, GLUT1, GLUT3, GLUT4 | Glucose metabolism | Cancer, cardiovascular disease, neurodegenerative diseases, infectious disease | Diagnostic, phenotypic, prognostic, intermediate endpoint |
| 18F-NaF | Hydroxyapatite | Bone remodeling | Primary and metastatic bone cancers, degenerative/inflammatory bone disease | Diagnostic, prognostic |
| 11C-choline | Choline kinase | Lipid metabolism | (Prostate) cancer | Diagnostic, phenotypic |
| 68Ga-DOTATATE | Somatostatin receptors | Somatostatin receptor density | NETs | Diagnostic, predictive |
| 18F-fluciclovine | LAT1 | Amino acid transport | (Prostate) cancer | Diagnostic, phenotypic |
| 82Rb | Na+/K+ ion exchange | Myocardial blood flow | Detection of CAD | Diagnostic |
| 13N-ammonia | Incorporation into glutamine by glutamine synthetase | Myocardial blood flow | Detection of CAD | Diagnostic |
| 123I-ioflupane | Presynaptic dopamine transporter | Dopamine transport | Movement disorders | Diagnostic |
| 18F-labeled florbetapir, florbetaben, and flutemetamol | Amyloid | Amyloid deposition | Progressive neurodegenerative diseases | Diagnostic, prognostic |
CAD = cardiovascular disease.